JeffreyLVacircaMD

Oncology • Port Jefferson Station, NY

Consultant in Oncology and Hematology

Join to view full profile

Dr. Vacirca is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vacirca's full profile

Already have an account?

Office
1500 Route 112
Bldg 4
Port Jefferson Station, NY 11776
Phone+1 631-574-8354

Fax+1 631-509-6559

Education & Training

Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 1998 - 2001
St. George's University School of MedicineClass of 1998

Certifications & Licensure

TN State Medical License 2019 - 2027
CT State Medical License 2019 - 2026
NY State Medical License 2001 - 2026
NJ State Medical License 2019 - 2025
SC State Medical License 2019 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Fellow (FACP) American College of Physicians, 2007

Clinical Trials

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 2
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Octagam 5% Versus Comparator Post Marketing Trial Start of enrollment: 2013 May 21
Completed
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Start of enrollment: 2014 Mar 01
Completed
Phase 3
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Start of enrollment: 2015 Dec 01
Completed
Join now to see all

Publications & Presentations

PubMed

Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
Martin Barnes, George Calcanes, Michael C Mosier, Jeffrey Vacirca, Zulfiqar Malik
American Health & Drug Benefits. 2021-12-01
Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
Martin Barnes, George Calcanes, Michael C Mosier, Jeffrey Vacirca, Zulfiqar Malik
American Health & Drug Benefits. 2021-09-01
Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data.
Celestia S. Higano, Andrew J. Armstrong, Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff
Cancer. 2020-06-15

Press Mentions

“It’s Crazy Money”: PBMs and the Need for TransparencyMarch 29th, 2023
Community Oncology: The Next 20 YearsMarch 25th, 2023
Annexus Health Raises $33 Million to Further Improve Patient Access and AffordabilityAugust 2nd, 2022
Join now to see all

Professional Memberships

American College of Physicians - ACP
Fellow